Skip to main content

Anifrolumab News

Anifrolumab Tied to Less Organ Damage for Patients With Lupus

THURSDAY, Feb. 20, 2025 – For patients with moderately to severely active systemic lupus erythematosus (SLE), anifrolumab is associated with less organ damage after 208 weeks compared with patients...

FDA Approves Saphnelo (anifrolumab) for Moderate to Severe Systemic Lupus Erythematosus

2 August 2021 – AstraZeneca’s Saphnelo (anifrolumab-fnia) has been approved in the US for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving ...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Systemic Lupus Erythematosus

Anifrolumab patient information at Drugs.com